

Van: ccmo_bi
Aan: ccmo_frontoffice
Cc: ccmo_eudract
Onderwerp: FW: NL67312.028.18: Notification Early Termination
Datum: dinsdag 7 april 2020 14:05:51
Bijlagen: [B7. EudraCT end of trial form .pdf](#)
[A1. Cover letter NL67312.028.18 dd 07Apr2020.pdf](#)

Van: PPD Netherlands (SM) <PPDNetherlands.SM@ppdi.com>

Verzonden: dinsdag 7 april 2020 14:04

Aan: ccmo_bi <bi@ccmo.nl>

CC: [REDACTED] <[REDACTED]@ppdi.com>

Onderwerp: NL67312.028.18: Notification Early Termination

Re: **Digital submission of Early Termination**
Protocol: **PVO-2A-201**
EudraCT number: **2017-002751-28**
NL number: **NL67312.028.18**

Dear members of the Central Committee on Research Involving Human Subjects,

With this letter we would like to notify the Competent Authority (Central Committee on Research Involving Human Subjects) of the early termination of the research entitled: *“A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas”* registered under number NL67312.028.18.

Please find attached to this email the full cover letter as well as supporting documents:

- A1. Cover letter NL67312.028.18 dd 07Apr2020
- B7. EudraCT end of trial form

Please address any enquiries to undersigned.
Thank you in advance.

Met vriendelijke groet / Kind regards,

[REDACTED]
5.1.2.e

Site and Patient Access – Global Site Intelligence and Activation

PPD

Bornweg 12C 6721 AH Bennekom, NL

Phone +31 (0)31865 [REDACTED]

Fax +31 (0)318 65 [REDACTED]

[REDACTED] [@ppdi.com](mailto:[REDACTED]@ppdi.com)

Upcoming OOO: 10Apr, 13Apr, 27Apr, 05May

This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.